Promoting α‐syn SAAs for a molecular‐based routine workup of synucleinopathies needs to be fully validated, by mandatorily addressing issues related to protocol and recombinant substrate standardization as well as those related to the quantitative response of the technique. Here, PCSK1N is linked to synucleinopathy.